PDS Biotech targets an interim progression-free survival readout in its Phase 3 trial with around 250 patients enrolled.
PDS Biotechnology Corporation has amended its VERSATILE-003 Phase 3 trial to include an interim analysis of progression-free survival (PFS). The trial now targets approximately 250 patients, reflecting significant progress in clinical execution.
Management highlighted the quarter’s focus on advancing clinical programs during its Q1 2026 earnings call. The amendment aims to accelerate data readouts, though no prior PFS benchmarks or consensus expectations were disclosed for comparison.
No immediate market reaction was reported following the announcement.